Sasha Fraser

As novel ADCs push beyond the boundaries of traditional therapies, bioanalytical teams face growing challenges in determining what to measure, why it matters, and how to generate meaningful data. This workshop will explore the evolving strategies needed to overcome analytical complexities, navigate limited regulatory guidance, and support the successful translation of next-generation modalities into the clinic.

Topics covered can Include:

• Exploring clinical bioanalytical strategies in the absence of modality-specific regulatory guidance
• Overcoming bioanalytical challenges for novel conjugates, including assay development, measurement complexity, and generating clinically meaningful data
• Tailoring measurement approaches across diverse modalities for non-traditional ADCs, immune stimulatory antibody conjugates, and antibody-oligonucleotide conjugates.